Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + rituximab versus cladribine + rituximab in front-line hairy cell leukemia
2021-001864-12Phase 2Active
- Sponsor
- University of Perugia
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vemurafenib, rituximab and cladribine in hairy cell leukemia (HCL) (2 arms), sponsored by University of Perugia. Primary endpoints: Efficacy primary endpoint, Safety primary endpoint and 1 more. Started Aug 2022; status: active.
02
Drugs
vemurafenibrituximabcladribine
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2021-001864-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001864-12.